Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2013 3
2014 1
2015 3
2016 2
2017 1
2018 1
2020 2
2021 2
2022 6
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year
Filters applied: . Clear all
Page 1
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
Gold R, Piani-Meier D, Kappos L, Bar-Or A, Vermersch P, Giovannoni G, Fox RJ, Arnold DL, Benedict RHB, Penner IK, Rouyrre N, Kilaru A, Karlsson G, Ritter S, Dahlke F, Hach T, Cree BAC. Gold R, et al. Among authors: hach t. J Neurol. 2022 Sep;269(9):5093-5104. doi: 10.1007/s00415-022-11166-z. Epub 2022 May 31. J Neurol. 2022. PMID: 35639197 Free PMC article. Clinical Trial.
Cryptococcal Meningitis Reported With Fingolimod Treatment: Case Series.
Del Poeta M, Ward BJ, Greenberg B, Hemmer B, Cree BAC, Komatireddy S, Mishra J, Sullivan R, Kilaru A, Moore A, Hach T, Berger JR. Del Poeta M, et al. Among authors: hach t. Neurol Neuroimmunol Neuroinflamm. 2022 Mar 22;9(3):e1156. doi: 10.1212/NXI.0000000000001156. Print 2022 May. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35318259 Free PMC article.
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series.
Sullivan R, Kilaru A, Hemmer B, Campbell Cree BA, Greenberg BM, Kundu U, Hach T, DeLasHeras V, Ward BJ, Berger J. Sullivan R, et al. Among authors: hach t. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 30;9(1):e1092. doi: 10.1212/NXI.0000000000001092. Print 2021 Nov. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34848501 Free PMC article.
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.
Ziemssen T, Bhan V, Chataway J, Chitnis T, Campbell Cree BA, Havrdova EK, Kappos L, Labauge P, Miller A, Nakahara J, Oreja-Guevara C, Palace J, Singer B, Trojano M, Patil A, Rauser B, Hach T. Ziemssen T, et al. Among authors: hach t. Neurol Neuroimmunol Neuroinflamm. 2022 Nov 22;10(1):e200064. doi: 10.1212/NXI.0000000000200064. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36414428 Free PMC article. Review.
Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?
Bharadia T, Vandercappellen J, Chitnis T, Eelen P, Bauer B, Brichetto G, Lloyd A, Schmidt H, King M, Fitzgerald J, Hach T, Hobart J. Bharadia T, et al. Among authors: hach t. Mult Scler J Exp Transl Clin. 2022 Jun 22;8(2):20552173221105642. doi: 10.1177/20552173221105642. eCollection 2022 Apr-Jun. Mult Scler J Exp Transl Clin. 2022. PMID: 35755007 Free PMC article.
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey.
Ziemssen T, Giovannoni G, Alvarez E, Bhan V, Hersh C, Hoffmann O, Oreja-Guevara C, Robles-Cedeño RR, Trojano M, Vermersch P, Dobay P, Khwaja M, Stadler B, Rauser B, Hach T, Piani-Meier D, Burton J. Ziemssen T, et al. Among authors: hach t. J Med Internet Res. 2021 Oct 6;23(10):e29558. doi: 10.2196/29558. J Med Internet Res. 2021. PMID: 34612826 Free PMC article.
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Ferrannini G, et al. Among authors: hach t. Diabetes Care. 2015 Sep;38(9):1730-5. doi: 10.2337/dc15-0355. Epub 2015 Jul 15. Diabetes Care. 2015. PMID: 26180105 Free PMC article.
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Arnold DL, Piani-Meier D, Bar-Or A, Benedict RH, Cree BA, Giovannoni G, Gold R, Vermersch P, Arnould S, Dahlke F, Hach T, Ritter S, Karlsson G, Kappos L, Fox RJ; EXPAND Clinical Investigators. Arnold DL, et al. Among authors: hach t. Mult Scler. 2022 Sep;28(10):1526-1540. doi: 10.1177/13524585221076717. Epub 2022 Mar 9. Mult Scler. 2022. PMID: 35261318 Free PMC article. Clinical Trial.
22 results